Relert 40 mg film-coated tablets

Spain
Brand name Relert 40 mg film-coated tablets
Form tablets, film-coated
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 64123
Relert 40 mg film-coated tablets tablets, film-coated

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

RELERT 40mg film-coated tablets

Eletriptan

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor or pharmacist.
  • This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, since it could harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

  1. What Relert is and what it is used for
  2. What you need to know before taking Relert
  3. How to take Relert
  4. Possible side effects
  5. Storage of Relert
  6. Package contents and additional information

1. What Relert is and what it is used for

Relert contains eletriptan as the active substance. Relert belongs to a group of medicines known as serotonin receptor agonists. Serotonin is a natural substance found in the brain that helps narrow blood vessels.

Relert can be used for the treatment of migraine headache with or without aura in adults. Before the migraine headache begins, you may experience a phase called "aura," during which visual disturbances, numbness, and speech disturbances may occur.

2. What you need to know before taking Relert

Do not take Relert:

  • If you are allergic (hypersensitive) to eletriptan or to any of the other ingredients of this medicine (listed in section 6).
  • If you have severe liver or kidney disease.
  • If you have moderate or severe high blood pressure, or untreated mild high blood pressure.
  • If you have heart problems [for example, heart attack, angina, heart failure, or significant abnormalities in heart rhythm (arrhythmia), transient and sudden narrowing of one of the coronary arteries].
  • If you have poor circulation (peripheral vascular disease).
  • If you have ever had a stroke (even if it was mild and lasted only a few minutes or hours).
  • If you have taken ergotamine or ergotamine-type medicines (including methysergide) within 24 hours before or after taking Relert.
  • If you are taking other medicines ending in “triptan” (for example sumatriptan, rizatriptan, naratriptan, zolmitriptan, almotriptan, and frovatriptan).

Inform your doctor and do not take Relert if you currently have or have previously had any of these conditions.

Warnings and precautions

Consult your doctor or pharmacist before taking Relert if:

  • You have diabetes.
  • You smoke or are undergoing nicotine replacement therapy.
  • You are a man over 40 years of age.
  • You are a postmenopausal woman.
  • You or a family member has coronary artery disease.
  • You have been informed that you may have an increased risk of heart disease; inform your doctor before taking Relert.

Repeated use of migraine medications

If you repeatedly use Relert or any other migraine treatment for several days or weeks, this may cause long-lasting daily headaches. Inform your doctor if this occurs, as you may need to stop treatment for a period of time.

Taking Relert with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might need to use any other medicines.

Taking Relert together with certain medicines may cause serious adverse effects. Do not take Relert if:

  • You have taken ergotamine or ergotamine-type medicines (including methysergide) within 24 hours before or after taking Relert.
  • You are taking other medicines ending in “triptan” (for example sumatriptan, rizatriptán, naratriptan, zolmitriptan, almotriptan, and frovatriptan).

Some medicines may affect how Relert works, or Relert itself may reduce the effectiveness of other medicines taken at the same time. These include:

  • Medicines used to treat fungal infections (for example ketoconazole and itraconazole).
  • Medicines used to treat bacterial infections (for example erythromycin, clarithromycin, and josamycin).
  • Medicines used to treat HIV/AIDS (for example ritonavir, nelfinavir, and indinavir).

The herbal preparation St. John’s wort (Hypericum perforatum) must not be taken at the same time as this medicine. If you are already taking St. John’s wort, consult your doctor before stopping its use.

Inform your doctor before starting treatment with eletriptan if you are taking certain medicines (commonly known as SSRIs* or SNRIs**) for depression or other mental disorders. These medicines may increase the risk of developing serotonin syndrome when used in combination with certain migraine medicines. See section 4 “Possible side effects” for more information about the symptoms of serotonin syndrome.

*SSRIs – Selective serotonin reuptake inhibitors.

**SNRIs – Serotonin and noradrenaline reuptake inhibitors.

Taking Relert with food and drink

Relert may be taken before or after food and drinks.

Pregnancy and breastfeeding

Consult your doctor or pharmacist before using any medicine.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.

Breastfeeding is not recommended for 24 hours after taking this medicine.

Driving and using machines

Relert, or the migraine itself, may cause drowsiness. This medicine may also cause dizziness. Therefore, you should avoid driving or operating machinery during a migraine attack or after taking this medicine.

Relert contains lactose, aluminium lake of orange-yellow dye (E110), and sodium

Lactose is a type of sugar. This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult with him before taking this medicine.

This medicine may cause allergic reactions because it contains aluminium lake of orange-yellow dye (E110). It may cause asthma, particularly in patients allergic to acetylsalicylic acid.

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; therefore, it is essentially “sodium-free”.

3. How to take Relert

Follow exactly the instructions for use of this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.

Adults

You may take the medicine at any time after the onset of a migraine headache, but it is best to take it as soon as possible. However, you should only take Relert during the headache phase of a migraine. Do not take this medicine to prevent a migraine attack.

  • The recommended usual starting dose is 40 mg (two tablets of Relert 20 mg or one tablet of Relert 40 mg daily, taken orally).
  • Swallow the tablet whole with some water.
  • If the first tablet does not relieve your migraine, you must not take a second tablet for the same attack.
  • If, after taking the first tablet, your migraine improves but then returns later, you may take a second tablet. However, you must wait at least 2 hours after taking the first tablet before taking the second one.
  • Do not take more than 80 mg (four tablets of Relert 20 mg or two tablets of Relert 40 mg) within 24 hours.
  • If you do not obtain relief with a dose of 40 mg (two tablets of Relert 20 mg or one tablet of Relert 40 mg), consult your doctor. Your doctor will decide whether your dose should be increased to 80 mg (four tablets of Relert 20 mg or two tablets of Relert 40 mg) for subsequent attacks.

Use in children and adolescents under 18 years of age

The use of Relert tablets is not recommended in children and adolescents under 18 years of age.

Patients over 65 years of age

The use of Relert tablets is not recommended in patients over 65 years of age.

Renal impairment

This medicine may be used in patients with mild or moderate kidney problems. In these patients, the recommended initial dose is 20 mg (one tablet of Relert 20 mg), and the total daily dose must not exceed 40 mg (two tablets of Relert 20 mg or one tablet of Relert 40 mg).

Hepatic impairment

This medicine may be used in patients with mild or moderate liver problems. Dose adjustments are not required for mild or moderate hepatic impairment.

If you take more Relert than you should

If you accidentally take more Relert than you should, contact your doctor immediately or go to the nearest hospital emergency department. Always take the medicine packaging with you, even if it is empty. Adverse effects of Relert overdose include high blood pressure and heart problems.

Contact your doctor, pharmacist, or call the Toxicology Information Service at telephone number 91 562 04 20 immediately, indicating the medicine and the amount taken.

It is recommended to bring the medicine's packaging and leaflet to the healthcare professional.

If you forget to take Relert

If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for forgotten doses.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Tell your doctor immediately if you experience any of the following symptoms after taking the medicine:

  • Sudden wheezing, difficulty breathing, swelling of the eyelids, face or lips, skin rash or itching (especially affecting the whole body), as these may be signs of a hypersensitivity reaction (allergy).
  • Pain and tightness in the chest, which may be severe and affect the throat. These may be symptoms of problems with blood circulation in the heart (ischaemic heart disease).
  • Signs and symptoms of serotonin syndrome, which may include restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, and overactive reflexes.

Other possible adverse effects include:

Frequent adverse effects:

(may affect up to 1 in 10 people)

  • Chest pain or tightness, palpitations, increased heart rate.
  • Dizziness, sensation of spinning (vertigo), headache, numbness, decreased sense of touch or pain.
  • Sore throat, sensation of tightness in the throat, dry mouth.
  • Abdominal and stomach pain, indigestion (upset stomach), nausea (a feeling of uneasiness and discomfort in the stomach or abdomen that leads to vomiting).
  • Muscle stiffness (increased muscle tone), muscle weakness, back pain, muscle pain.
  • General feeling of weakness, sensation of heat, chills, runny nose, sweating, tingling or abnormal sensation, flushing, pain.

Uncommon adverse effects:

(may affect up to 1 in 100 people)

  • Difficulty breathing, yawning.
  • Swelling of the face or hands and feet, inflammation or infection of the tongue, skin rash, itching.
  • Increased sensitivity to touch or pain (hyperesthesia), loss of coordination, reduced or slowed movements, tremor, slurred speech.
  • Feeling detached from oneself (depersonalization), depression, abnormal thinking, feeling agitated, feeling confused, changes in mood (euphoria), periods of unresponsiveness (stupor), general feeling of discomfort, illness or malaise, sleep problems (insomnia).
  • Loss of appetite and weight loss (anorexia), taste disturbances, thirst.
  • Degeneration of the joints (osteoarthritis), bone pain, joint pain.
  • Increased need to urinate, problems urinating, excessive urine output, diarrhea.
  • Abnormal vision, eye pain, light sensitivity, dry eyes or watery eyes.
  • Ear pain, ringing in the ears (tinnitus).
  • Poor circulation (peripheral vascular disorder).

Rare adverse effects:

(may affect up to 1 in 1,000 people)

  • Shock, asthma, urticaria, skin disorders, swollen tongue.
  • Chest or throat infection, enlarged lymph nodes.
  • Decreased heart rate.
  • Emotional lability (mood changes).
  • Degeneration of the joints (arthritis), muscle disturbance, twitching.
  • Constipation, inflammation of the oesophagus, belching.
  • Breast pain, heavy or prolonged menstruation.
  • Eye infection (conjunctivitis).
  • Voice changes.

Other adverse effects described include fainting, high blood pressure, inflammation of the large intestine, vomiting, blood vessel and brain accidents, inadequate blood supply to the heart, heart attack, spasm of the arteries and heart muscles.

Your doctor may carry out regular blood tests to check for increased liver enzymes or any blood-related problems.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Relert

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the container. The expiry date refers to the last day of the month indicated.

PVC/Aclar/Aluminum blisters: No special storage conditions are required.

HDPE bottles: Store in the original container. Keep the container tightly closed to protect from moisture.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to properly dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Relert 40 mg film-coated tablets

The active substance is eletriptan (as eletriptan hydrobromide).

Each Relert 40 mg film-coated tablet contains 40 mg of eletriptan (as hydrobromide).

The other components are: microcrystalline cellulose, lactose monohydrate, sodium croscarmellose, magnesium stearate, titanium dioxide (E-171), hypromellose, glycerol triacetate, and orange-yellow FCF aluminium lake (E-110) (see section 2).

Appearance of the product and contents of the pack

Relert tablets are orange, round, film-coated tablets.

Relert 40 mg film-coated tablets are marked with “VLE” on one side and “REP 40” on the other.

Relert is available in opaque PVC/Aclar/aluminium blisters containing 2, 3, 4, 5, 6, 10, 18, 30 and 100 tablets or in HDPE bottles with a child-resistant HDPE/PP closure containing 30 and 100 tablets.

Only certain pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Viatris Healthcare, S.L.

Calle General Aranaz, 86, 3rd floor

28027 Madrid

Spain

Manufacturer

Pfizer Italia S.r.l.,

Località Marino del Tronto

63100 Ascoli Piceno

Italy

Local representative

Viatris Pharmaceuticals, S.L.U.

Calle General Aranaz, 86

28027 Madrid

Spain

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

Relert 20 mg and 40 mg film-coated tablets: Belgium, Finland, Luxembourg, Portugal, Spain, United Kingdom.

Relpax 20 mg and 40 mg film-coated tablets: Austria, Denmark, France, Germany, Greece, Iceland, Ireland, Italy, Norway, Spain, Sweden, Netherlands, United Kingdom.

Date of the most recent revision of this leaflet: January 2021

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/